Iovance Biotherapeutics, Inc.
IOVA
Classement en actions
#2795
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Prix de l'action
$14.87
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$6.74B
Changement (1 jour)
4.64%
Changement (1 an)
555.03%
Pays
US
Échange Iovance Biotherapeutics, Inc. (IOVA)
Catégorie
Healthcare
Ratio P/B pour Iovance Biotherapeutics, Inc. (IOVA)
Ratio P/B au October 2026 TTM : 8.69
Selon les derniers rapports financiers et le cours de l'action de Iovance Biotherapeutics, Inc., le ratio cours/valeur comptable actuel (TTM) est 8.69. À la fin de 2023, le ratio P/B était de 3.27.
Historique du ratio P/B pour Iovance Biotherapeutics, Inc. de 2008 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| 2026 (TTM) | 8.69 | 187.79% |
| 2024 | 3.02 | -7.66% |
| 2023 | 3.27 | 60.54% |
| 2022 | 2.04 | -56.76% |
| 2021 | 4.71 | -51.81% |
| 2020 | 9.77 | -15.09% |
| 2019 | 11.51 | 523.36% |
| 2018 | 1.85 | -48.53% |
| 2017 | 3.59 | 55.91% |
| 2016 | 2.30 | -30.18% |
| 2015 | 3.30 | -24.84% |
| 2014 | 4.38 | -24.70% |
| 2013 | 5.82 | -475.21% |
| 2012 | -1.55 | -73.87% |
| 2011 | -5.94 | -104.65% |
| 2010 | 127.82 | -101.69% |
| 2009 | -7.55K | -112.90% |
| 2008 | 58.49K | 0.00% |
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| 6.251 | -28.08% |
US
|
|
| 13.2547 | 52.51% |
US
|
|
| 4.208 | -51.58% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -28.87% |
NL
|
